We have examined the mononuclear cell fraction from 35 individuals, 18 with hematologic malignancies and 17 healthy controls for the presence of cell surface-associated plasminogen activator (PA) activity. PA activity was found on the cell surface of 10 out of 12 samples from patients with acute leukemia. In addition to active urokinase (uPA) found on the cell surface in four out of five acute myeloid leukemia patients, tissue-type PA activity was detected in the same samples (3 of 5). Two out of four samples from acute lymphoid leukemia displayed only uPA activity and three out of three samples from biphenotypic LASMINOGEN activation on the surface of tumor P cells has been implicated in cell migration and tumor cell invasion.',' Urokinase-mediated plasminogen activation (uPA) takes place on the cell surface where the different components of the enzymatic pathway operate in a cellbound uPA binds to the cell surface through a high-
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We have examined the mononuclear cell fraction from 35 individuals, 18 with hematologic malignancies and 17 healthy controls for the presence of cell surface-associated plasminogen activator (PA) activity. PA activity was found on the cell surface of 10 out of 12 samples from patients with acute leukemia. In addition to active urokinase (uPA) found on the cell surface in four out of five acute myeloid leukemia patients, tissue-type PA activity was detected in the same samples (3 of 5). Two out of four samples from acute lymphoid leukemia displayed only uPA activity and three out of three samples from biphenotypic LASMINOGEN activation on the surface of tumor P cells has been implicated in cell migration and tumor cell invasion.',' Urokinase-mediated plasminogen activation (uPA) takes place on the cell surface where the different components of the enzymatic pathway operate in a cellbound uPA binds to the cell surface through a highaffinity receptor (kd -IO-" mol/L) that can bind pro-uPA, active uPA, and uPA complexed with PA IS.*-'^ Plasminogen-binding proteins are less well characterized because plasminogen seems to bind to many different cell surface proteins with low affinity (kd -m0l/L).~7"3'' Although cell-bound plasmin is not inhibited by the high molecular weight plasmin inhibitors present in plasma and serum, plasmin generation on the cell surface is regulated by inhibiting receptor-bound uPA with plasminogen activator inhibitors PA IS).^-^,'^-'' According to recent results, the presence of uPA is a strong adverse prognostic marker in the progression and overall survival time for progressive breast cancer implying early relapse and the tendency for metastatic disease.16*" Earlier work on myeloid leukemia patients has shown that their cells produced either tissue-type PA (tPA) or uPA in culture. The type of PA produced was found to have prognostic significance because patients whose cells secreted tPA failed to respond to chemotherapy, whereas 80% of those whose cells secreted uPA entered remission." Also, normal myeloid precursor cells were found to secrete PAS, and the type of the secreted activator was differentiation-linked.I9 Although these studies have shown the ability of normal and malignant myeloid cells to produce PAS in cell culture conditions, we found it ofinterest to study ifwe could detect plasminogen activators or plasmin on the surface of freshly isolated leukemia cells and whether myeloid and lymphoid leukemia cells would differ in this respect.
Leukemic cells tend to infiltrate the bone marrow and through bamers such as the blood-brain barrier, which will stop normal hematopoietic cells. Monocytoid leukemic blasts (French-American-British classification M4 and M5) have a tendency to infiltrate the skin and mucous membranes. Moreover, it has been shown that experimental invasion of activated monocytes through the amniotic membrane is dependent on the activity of cell-bound urokinase" and that, in monocytes induced to migrate, the uPA is found on the leading edge of the cell." The uPA receptor is linked to the plasma membrane through a glycolipid ancho?' that seems to render the unoccupied receptors freely mobile in the plane of the plasma membrane on the cell surface.23 An independently characterized monocyte activation antigen (Mo3) was found to be identical to the uPA receptor. 24 In our previous work we have characterized plasminogen activators found in continuous leukemia cell cultures and on the surface of leukemia cells grown in culture. We found active two-chain urokinase in the serum-free growth medium of many leukemia cell lines and in the acid-elutable cell surface-bound fraction of many cultured leukemia cell^.',^^,'^ The plasminogen activation cascade was continuously turned on on the surface of leukemia cells grown in culture, driven by the activity of endogenous cell-bound uPA and serum plasminogen." Because active urokinase could be found on the surface of established leukemia cells grown in normal cell culture conditions, we were interested to see if freshly isolated leukemic cells express either of the plasminogen activators or active plasmin on their cell surface.
MATERIALS AND METHODS
Patient samples. Blood and/or bone marrow samples were obtained from patients with suspected acute or chronic leukemia at the time of diagnosis before any chemotherapy except for patient 4, whose blood and bone marrow were investigated during treatment. Thirty-seven samples from 35 individuals were studied. Blood sam-
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ples from healthy volunteers were used as controls. Mononuclear cells were separated by Ficoll-Hypaque centrifugation and, for enzymatic studies, resuspended in RPMI-1640 medium supplemented with 0.1% bovine serum albumin (BSA). The diagnosis of leukemia was based on clinical suspicion, differential cell counts, morphology, and immunophenotyping. Morphology was evaluated on May-Griinwald-Giemsa stained cytospin preparations and immunophenotype was analyzed using a panel of monoclonal antibodies (MoAbs) and flow cytometry (FACScan; Becton Dickinson, Mountain View, CA). The panel of MoAbs used in phenotyping acute leukemias included antibodies against the lymphoid-associated antigens CD2, 7, 10, 19, and 20 and myeloid antigens CD13, 14, and 33. When indicated, these were complemented with antibodies against CD 1 1 c, CD36, and terminal deoxynucleotidyl transferase (TdT) used in immunoperoxidase staining and against intracellular Ig p heavy chain detected by immunofluoresence staining of cytospin preparations. Samples were scored positive when more than 20% of blasts were stained. Biphenotypic acute leukemia was diagnosed when blasts were positive for two or more antigens associated with each lymphoid and myeloid lineage. Determination of Ig light chain clonality was done in cases of chronic lymphocytic leukemia (CLL).
For enzymatic assays, the cells were washed with Dulbecco's phosphate-buffered saline (PBS) supplemented with 0.2% BSA (DBSA) and eluted first with 10 mmol/L tranexamic acid (KabiVitrum, Uppsala, Sweden) in DBSA (5 X lo6 cells/200 pL), and then with acid glycine (20 mmol/L glycine, 100 mmol/L NaC1, pH Immunocapture assay for PAS. PAS were assayed in a microimmunocapture assay for either uPA or tPA.5325s29 Briefly, samples to be tested were bound in triplicate to microwell plates coated either with rabbit IgG to human uPA (No. 389; American Diagnostica, Greenwich, CT) or goat IgG to human tPA (No. 387; American Diagnostica). After the binding step the wells were washed and plasminogen, purified from fresh human plasma by affinity to lysine, was added. Plasmin formed by the antibody-bound activators was measured by its thioesterase activity to Z-lysine thiobenzyl ester (Peninsula Laboratories, Belmont, CA)." The percentage of active two-chain uPA out of total uPA was estimated by the use of the serine proteinase inhibitor nitrophenyl-p-guanidinobenzoate (2 pmol/L NPGB; Sigma) after the binding step to the microplates. The neutralized acid eluates were run in nonreducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using an 8% polyacrylamide gel. After washing out SDS with Triton X-100, the gel was incubated on a wet film of agarose containing 2.5% milk powder with (detection of PAS) or without plasminogen (detection of plasmin)." The zymograms were photographed after exposure at 37°C. Human uPA (0.5 IU/mL), human tPA (0.5 IU/mL), and human plasmin (KabiVitrum; 0.5 pg/mL) were used as standards in zymography, for Zymography of plasmin or PAS.
each zymogram the amounts of standard PAS used were the same and also other test conditions were kept constant. The development of each zymogram was followed daily, the highest activities being strong positives already after 24 hours of incubation. The values for zymography in Table 1 (graded as -to ++++) are relative values after visual inspection of the zone of the lysis, photography, and comparison to the PA standards (0.5 IU/mL) after 2 days of development. To assay the type of plasminogen activator found by zymography, an anticatalytic monoclonal antibody to human urokinase (10 pg/mL in DBSA) was included between the PAGE-gel and the casein layer. The antibody was a kind gift from Dr Gunilla Hayer-Hansen, Finsen Laboratory, Copenhagen, Denmark.
RESULTS
The purpose of this study was to examine the presence of PAS (uPA and tPA) and plasmin activity on the surface of the mononuclear cells separated from leukemic bone marrow or blood samples. PAS were detected by two independent assays, both based on PA enzymatic activity. We used specific immunocapture assays for uPA and tPA, as detailed in Materials and Methods. In the second assay, the samples were analyzed in SDS-PAGE followed by zymograPhY.
In the course of the study, we examined 13 bone marrow samples and 24 blood samples from 35 individuals. 12 bone marrow samples were obtained from patients with hematologic disorders (listed in Table I ) and one was from a patient with suspected lymphoma whose bone marrow turned out to be normal (No. 13). Eight blood samples were from leukemic patients (No. 4B, IOB, 14 to 19 in Table I ) and 16 blood samples from healthy volunteers (No. 20 to 35). The results are shown in Table 1 and Fig 1, where the patients are numbered from 1 to 35. When both bone marrow and blood samples were taken from the same individual, the samples are designated A (bone marrow) and B (blood). The percentage and immunophenotype of the leukemic blasts in the samples are also listed in Table I .
We found that out of the 37 samples studied, all 10 samples that were clearly uPA positive, with either or both ofthe detection methods, were either bone marrow or blood samples from patients with acute leukemia (No. 1,2,3 Three out of 4 AML bone marrow samples expressed tPA activity in addition to uPA activity on their mononuclear cell surface when analyzed by the immunocapture assay (No. 1, 2, 4A). Mononuclear cells from healthy persons were tPA negative in our study.
The RSD calculated from triplicate determinations of positive patient samples was 4.5% in the immunocapture assay for uPA and 5.1 % in the assay for tPA. Figure 2 shows an example of detection of both plasminogen activators from a patient's bone marrow sample (No. 4). The molecular weight of tPA found in the tranexamic acid eluate of the mononuclear cells (Fig 2, lane APL-TA) corresponds to the tPA standard (lane tPA) and is clearly higher than that of uPA found in the low pH eluate of the same cells (Fig 2, lane APL-pH 3.0) . The uPA standard is shown in lane uPA. In addition, Fig 2 shows that most of the cellbound tPA is eluted with tranexamic acid (lane APL-TA), whereas the low pH eluate contains mainly uPA (lane APLpH 3.0).
In Figure 1 we have plotted the uPA activity detected by the immunocapture assay of each sample against the uPA activity in zymography. In most samples (32 of 37) the results obtained by uPA immunocapture assay and zymography are in a reasonably good correlation. This is seen for example in the case of sample No. 1; the size of the lysis zone obtained in zymography (compared with the lysis zone of uPA standard 0.5 IU/mL) corresponds well to the activity of 0.425 IU/mL obtained by immunocapture assay (Table  1 , zymogram not shown). In four cases of acute leukemia there was a clear discrepancy between the results obtained using the two methods (Table 1, No. 2,4A, 4B, 16) , which might be related to complex formation between uPA and unidentified proteins, possibly inhibitors.
In five cases of leukemia (No. 1, 2, 4B, 15, 16), we have confirmed with the use of an anticatalytic monoclonal antibody to uPA, that the plasminogen-dependent proteolytic activity in the zymograms was uPA (results not shown).
For Prolonged zymography of the samples without plasminogen added to the casein overlay should detect plasmin (detection limit > 100 ng/mL) and other serine proteinase activities, but no such activity was found in any of the samples.
DISCUSSION
In the present study we have shown that acute leukemia is unequivocally associated with the presence of PAS, mostly uPA on the surface ofthe leukemia cells. Although the clinical material was small, we could show that out of the 37 samples studied the IO samples that had significant uPA activity were from patients with acute leukemia. The cells expressing PA activity on their surface were most likely the leukemic blasts because in most of the uPA-positive samples the mononuclear cell population contained 90% to 100% blasts. Patients with chronic leukemia or lymphoma and healthy persons had negligible or no uPA activity (0 to 0.010 IU/mL) on the surface of their blood mononuclear cells. In the detection of uPA activity we used two independent methods with good correlation of the results. Furthermore we could show that a significant proportion of uPA was in the active form as we have earlier shown for cultured leukemia cells contrasting the findings from cultured solid tumor cell
We did not see any differences in uPA activity related to the lineage of acute leukemia, high and relatively low uPA activities were found in both AML and ALL samples. On the contrary, CLL cells from four patients did not have detectable PA activity on their surface. Samples from marrow and peripheral blood gave similar results and suggest that uPA activity on the cell-surface does not correlate with tissue invasiveness of CLL cells because these cells are known to readily penetrate subendothelial tissues.
We found that three out of four bone marrow samples from patients with AML expressed tPA activity in addition to uPA. This finding is in agreement with the results published by Wilson et who found that myeloid leukemia cells in culture produced either one or both plasminogen activators and that. at the earlier stages of differentiation, the precursors of myeloid cells produced mainly tPA. We could also confirm the earlier finding that tPA binds to the cell surface by sites that have affinity to lysine33 because most cell-bound tPA could be eluted from the patient cells with tranexamic acid, which competes for these binding sites.
The time interval between blood collection and elution of enzyme activity for assay seemed critical in our series. When the mononuclear cell layer was separated right after the venipuncture from control blood samples very low (<O.OIO IU/mL) uPA activities could be found ( Table 1, sample No. 20 through 25). When another set of control cells was let to stand at room temperature for I hour before separation of the mononuclear cell layer, the activities became barely detectable to negative (Table l , sample No. 26 through 35). Processing of the leukemia samples for PA assay invariably took more than 3 hours suggesting that the difference in PA activity betweencontrol and leukemia samples was even greater than we detected.
Zymography might be less sensitive for the detection of tPA than for uPA because only the sample with the highest For personal use only. on September 24, 2017. by guest www.bloodjournal.org From tPA activity in immunocapture assay (No. 4A) was also positive by zymography (Fig 2, lane APL-TA) . Prolonged development (1 week) ofthe zymograms showed faint uPA activity in almost all samples (results not shown). This was not surprising because the method is very sensitive and at least activated monocytes have been reported to produce uPA.34*35 It can be suspected that there is always a small proportion of activated cells in the circulation. In four cases of acute leukemia there was a clear discrepancy between the results obtained with the two methods. Samples that contained uPA activity by zymography had no or only low uPA activity in the immunocapture assay (Table 1 , Nos. 2, 4A, 4B, 16). Such results could be expected if the uPA in the sample was noncovalently bound either to an inhibitor or to another protein inhibiting the binding of uPA to the immunocapture plate. 36 We found PA activity but no plasmin on the leukemia cells. However, in most patients the cell-surface bound uPA was in an active form. This finding implies that the proenzyme produced by the cells had been activated by a serine proteinase, most likely plasmin. The turn-over rate of cellbound plasmin could be so fast that plasmin is not detectable when handling of the sample takes several hours.
Further work should clarify if the amount of uPA activity found on the surface of acute leukemia cells has any correlation with the prognosis. Nevertheless, PA activity on the surface of leukemic blasts could influence the fibrinolytic state of the patient and contribute to the bleeding tendency caused by thrombocytopenia; especially patients with acute promyelocytic leukemia (APL) who encounter severe episodes of bleeding associated with disseminated intravascular coagulation (DIC) at the induction of remi~sion.~' We studied one patient with APL whose bone marrow blasts had high levels of both tPA and uPA activity on their surface. DIC is a complex sequence of proteolytic events that start with coagulation and, as a consequence of counteracting fibrinolytic events, result in a net fibrinolytic state. Lower than normal plasma levels of a,-plasmin-inhibitor have been reported in patients with DIC38,39 suggesting that plasminogen activation is occumng and consuming plasmin inhibitors. The excessive cell-surface plasminogen activation may also lead to consumption of fibrinogen and other clotting factors and may have a role in the generation of hemorrhage, a common complication in acute leukemia. 40 Release of active plasmin from the cell surface of leukemia cellsz7 would lead to consumption of circulating plasmin inhibitors. 40 In that case, the deleterious effects of plasmin generation on the fibrinolytic balance could be reduced in patients with acute leukemia by simultaneous administration of tranexamic acid and heparin.394'
